Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India

Santhanam, Sham; Murugesan, Hema; Nambi, Thilagavthy; Natarajan, Raja; Mohanasundaram, Kavitha

doi:10.4103/injr.injr_82_20

Cited by 2 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study in India shows that 85% of patients developed Remission and low disease activity by DAS28 ESR in PsA patients. 18 PASI 75 response is comparable to a recent study in China, where 441 patients of plaque psoriasis were enrolled, and PASI 75 was achieved in 97.7% & 87.2% of patients, with a dosage of 300mg Secukinumab and 150mg Secukinumab respectively. 19 Regarding the safety of Secukinumab, the most frequent AEs were upper respiratory tract infections during the 24 weeks.…”

Section: Discussionsupporting

confidence: 79%

“…A recent study showed ASDAS improvements in 76% of patients, and 90% showed BASDAI 50 improvements in AS patients at 24 weeks. 18 The Phase-III MEASURE, one extension study, also shows promising results, where ASAS 20/40 responses were 78.6/65.2% and improved BASDAI 50 responses at five years. 19 The efficacy data of Secukinumab in PsA patients in our study shows promising results, with 61.9% of patients reaching the goal of Remission and Low disease activity at 12 weeks and 94.7% of patients at 24 weeks.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Short-term Efficacy and Safety of Secukinumab in Pakistani Patients with Ankylosing Spondylitis and Psoriatic Arthritis

Ghani,

Saeed,

Malik

et al. 2023

PAFMJ

View full text Add to dashboard Cite

Objective: To determine the short-term efficacy and safety of Secukinumab in Pakistani patients with ankylosing spondylitis and psoriatic arthritis in regular clinical practice. Study Design: Case series. Place and Duration of Study: Department of Rheumatology, National Hospital and Medical Centre, Lahore Pakistan from Aug 2019 to Feb 2021. Methodology: Patients diagnosed with ankylosing spondylitis according to assessment of spondyloarthritis International Society criteria and psoriatic arthritis according to classification criteria for psoriatic arthritis (CASPAR), who were started on Secukinumab, were enrolled. Disease activity scores and adverse events were recorded in the 12th and 24th weeks. The primary outcomes were remission and low disease activity, and the secondary outcomes were the recording of Adverse events on each visit. Results: There were 42 patients registered. The mean duration of disease was 11.86±7.31 years for AS and 9.19±4.87 years for PsA patients. At 24 weeks of follow-up, 10% of patients discontinued treatment, 73.7% of AS patients, and 94.7% of PsA patients achieved complete remission or low disease activity. No significant AEs were noted at 24 weeks, except for upper respiratory tract infections. One patient developed a lower respiratory tract infection after 24 weeks of treatment, and one died during treatment (possible myocardial infarction). Conclusion: Secukinumab was effective and safe in patients with Ankylosing Spondylitis and Psoriatic Arthritis in this study,despite advanced disease with long disease duration.Keywords: Ankylosing spondylitis, Efficacy, Psoriatic arthritis, Safety, Secukinumab.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 97%